172 related articles for article (PubMed ID: 20698721)
1. Tremelimumab.
Drugs R D; 2010; 10(2):123-32. PubMed ID: 20698721
[TBL] [Abstract][Full Text] [Related]
2. Tremelimumab, a fully human monoclonal IgG2 antibody against CTLA4 for the potential treatment of cancer.
Tarhini AA; Kirkwood JM
Curr Opin Mol Ther; 2007 Oct; 9(5):505-14. PubMed ID: 17932815
[TBL] [Abstract][Full Text] [Related]
3. Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CP-675,206), a fully human monoclonal antibody.
Camacho LH
Expert Opin Investig Drugs; 2008 Mar; 17(3):371-85. PubMed ID: 18321236
[TBL] [Abstract][Full Text] [Related]
4. Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers.
Tarhini AA; Kirkwood JM
Expert Opin Biol Ther; 2008 Oct; 8(10):1583-93. PubMed ID: 18774925
[TBL] [Abstract][Full Text] [Related]
5. Ipilimumab.
Drugs R D; 2010; 10(2):97-110. PubMed ID: 20698719
[TBL] [Abstract][Full Text] [Related]
6. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206).
Ribas A
Oncologist; 2008; 13 Suppl 4():10-5. PubMed ID: 19001146
[TBL] [Abstract][Full Text] [Related]
7. Clinical development of the anti-CTLA-4 antibody tremelimumab.
Ribas A
Semin Oncol; 2010 Oct; 37(5):450-4. PubMed ID: 21074059
[TBL] [Abstract][Full Text] [Related]
8. The role of the CTLA4 blockade in the treatment of malignant melanoma.
Cranmer LD; Hersh E
Cancer Invest; 2007 Oct; 25(7):613-31. PubMed ID: 18027152
[TBL] [Abstract][Full Text] [Related]
9. Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer.
Ribas A; Hanson DC; Noe DA; Millham R; Guyot DJ; Bernstein SH; Canniff PC; Sharma A; Gomez-Navarro J
Oncologist; 2007 Jul; 12(7):873-83. PubMed ID: 17673618
[TBL] [Abstract][Full Text] [Related]
10. CTLA-4 blockade in tumor models: an overview of preclinical and translational research.
Grosso JF; Jure-Kunkel MN
Cancer Immun; 2013; 13():5. PubMed ID: 23390376
[TBL] [Abstract][Full Text] [Related]
11. Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications.
Calabrò L; Danielli R; Sigalotti L; Maio M
Semin Oncol; 2010 Oct; 37(5):460-7. PubMed ID: 21074061
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer.
Chung KY; Gore I; Fong L; Venook A; Beck SB; Dorazio P; Criscitiello PJ; Healey DI; Huang B; Gomez-Navarro J; Saltz LB
J Clin Oncol; 2010 Jul; 28(21):3485-90. PubMed ID: 20498386
[TBL] [Abstract][Full Text] [Related]
13. CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans.
Huang RR; Jalil J; Economou JS; Chmielowski B; Koya RC; Mok S; Sazegar H; Seja E; Villanueva A; Gomez-Navarro J; Glaspy JA; Cochran AJ; Ribas A
Clin Cancer Res; 2011 Jun; 17(12):4101-9. PubMed ID: 21558401
[TBL] [Abstract][Full Text] [Related]
14. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).
Weber J
Oncologist; 2008; 13 Suppl 4():16-25. PubMed ID: 19001147
[TBL] [Abstract][Full Text] [Related]
15. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells.
Vonderheide RH; LoRusso PM; Khalil M; Gartner EM; Khaira D; Soulieres D; Dorazio P; Trosko JA; Rüter J; Mariani GL; Usari T; Domchek SM
Clin Cancer Res; 2010 Jul; 16(13):3485-94. PubMed ID: 20479064
[TBL] [Abstract][Full Text] [Related]
16. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy.
Callahan MK; Wolchok JD; Allison JP
Semin Oncol; 2010 Oct; 37(5):473-84. PubMed ID: 21074063
[TBL] [Abstract][Full Text] [Related]
17. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies.
O'Day SJ; Hamid O; Urba WJ
Cancer; 2007 Dec; 110(12):2614-27. PubMed ID: 18000991
[TBL] [Abstract][Full Text] [Related]
18. Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo.
Suarez N; Alfaro C; Dubrot J; Palazon A; Bolaños E; Erro L; Hervas-Stubbs S; Martinez-Forero I; Morales-Kastresana A; Martin-Algarra S; Sangro B; Lecanda F; Perez-Gracia JL; Gonzalez A; Melero I
Int J Cancer; 2011 Jul; 129(2):374-86. PubMed ID: 20853321
[TBL] [Abstract][Full Text] [Related]
19. What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?
Robert C; Ghiringhelli F
Oncologist; 2009 Aug; 14(8):848-61. PubMed ID: 19648604
[TBL] [Abstract][Full Text] [Related]
20. CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues.
Phan GQ; Weber JS; Sondak VK
Ann Surg Oncol; 2008 Nov; 15(11):3014-21. PubMed ID: 18716842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
